Hikma reports 3.35 billion dollars in annual revenue
The drugmaker reported 2025 revenue of 3.35 billion dollars on Thursday. Growth was led by the injectables division and strong demand across its key markets.
Hikma Pharmaceuticals PLC has reported an increase in its annual revenue for 2025, supported by the strong performance of its injectables division and robust demand across its primary global markets. The company, which is a major player in the United Kingdom pharmaceutical sector, saw its total revenue rise to $3.35 billion for the year. This figure represents a notable improvement over the $3.13 billion in revenue reported during the 2024 fiscal period. The injectables segment continues to serve as a critical growth engine for the firm, benefiting from sustained market needs and operational efficiencies. These latest financial results underscore the company's ability to maintain a positive growth trajectory and capitalize on demand within its core operating regions.
